<DOC>
	<DOCNO>NCT00016172</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine ZD0473 doxorubicin treat patient advance solid tumor lymphoma .</brief_summary>
	<brief_title>ZD0473 Doxorubicin Treating Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ZD0473 doxorubicin HCl liposome patient advance metastatic solid tumor lymphoma . II . Determine qualitative quantitative toxic effect regimen patient population . III . Determine pharmacokinetics drug patient population . IV . Determine antitumor activity regimen patient population . OUTLINE : This dose-escalation study . Patients receive doxorubicin HCl liposome IV 60 minute follow ZD0473 IV 60 minute day 1 . Treatment repeat every 28 day maximum 6 course absence disease progression unacceptable toxicity . Patients partial response ( PR ) complete response ( CR ) may continue treatment disease progression 2 course maximum response . Cohorts 3-6 patient receive escalate dos doxorubicin HCl liposome ZD0473 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 3 6 patient experience dose-limiting toxicity . Patients follow 4 week 3 month . Patients PR CR ongoing continue follow-up every 3 month relapse . PROJECTED ACCRUAL : Approximately 24 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic solid tumor lymphoma Refractory standard curative therapy OR No curative therapy exist Serologically , clinically , and/or radiographically assessable disease No newly diagnose brain metastasis Intracranial disease stable least 6 month allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST ALT great 2.0 time ULN Alkaline phosphatase great 2.0 time ULN Renal : Creatinine great ULN Creatinine clearance least 60 mL/min Cardiovascular : Ejection fraction least 50 % Other : No underlie medical condition would preclude study uncontrolled No active serious infection No neurotoxicity preexist grade 3 high neuropathy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 5 day since prior immunotherapy Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas similar compound ) No 3 prior chemotherapy regimens metastatic disease No prior anthracycline exposure exceed 300 mg/m2 doxorubicin No prior doxorubicin HCl liposome Endocrine therapy : At least 5 day since prior hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy recover No prior radiotherapy 30 % function bone marrow Surgery : At least 3 week since prior major surgery Other : No concurrent experimental drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>